<DOC>
	<DOCNO>NCT00365846</DOCNO>
	<brief_summary>The purpose study see campath-1H use first time renal transplant subject prevent rejection reduce overall amount anti-rejection medication patient take daily basis .</brief_summary>
	<brief_title>`` A Pilot Study Determine Safety Campath-1H ( Anti-CD52 ) Therapy Primary Renal Allograft Transplantation ''</brief_title>
	<detailed_description>Twenty nine primary recipient either live donor decease donor renal transplant enrol study . Subjects administer two 20mg dos Campath-1H antibody therapy ( Day 0 Day 1 ) combination short course corticosteroid , maintenance sirolimus . Subjects follow 3 year compare incidence severity rejection episode , complication related immunosuppression , include infection , malignancy adverse event . All subject underwent protocol renal transplant biopsy 6 12 month ( unless medically contraindicate ) .</detailed_description>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>primary renal transplant ( HLA identical ) age 1860 year recipient panel reactive antibody level &gt; 10 % recipient DCD kidney prior organ transplant multiorgan transplant recipient subject currently receive systemic corticosteroid pregnant lactating subject history Hepatitis B , C HIV positivity recipient kidney cold ischemia time &gt; 36 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>prevent kidney rejection</keyword>
</DOC>